Selection of thioaptamers for diagnostics and therapeutics

Xianbin Yang, He Wang, David Beasley, David E. Volk, Xu Zhao, Bruce A. Luxon, Lee O. Lomas, Norbert K. Herzog, Judith Aronson, Alan Barrett, James F. Leary, David G. Gorenstein

Research output: Chapter in Book/Report/Conference proceedingConference contribution

22 Citations (Scopus)

Abstract

Thioaptamers offer advantages over normal phosphate ester backbone aptamers due to their enhanced affinity, specificity, and higher stability, largely due to the properties of the sulfur backbone modifications. Over the past several years, in vitro thioaptamer selection and bead-based thioaptamer selection techniques have been developed in our laboratory. Furthermore, several thioaptamers targeting specific proteins such as transcription factor NF-κ and AP-1 proteins have been identified. Selected thioaptamers have been shown diagnostic promise in proteome screens. Moreover, some promising thioaptamers have been shown in preliminary animal therapeutic dosing to increase survival in animal models of infection with West Nile virus.

Original languageEnglish (US)
Title of host publicationAnnals of the New York Academy of Sciences
Pages116-119
Number of pages4
Volume1082
DOIs
StatePublished - Oct 2006

Publication series

NameAnnals of the New York Academy of Sciences
Volume1082
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

Neurofibromin 1
West Nile virus
Transcription Factor AP-1
Protein Transport
Proteome
Sulfur
Esters
Animals
Animal Models
Phosphates
Infection
Viruses
Proteins
Transcription Factors
Therapeutics
In Vitro Techniques

Keywords

  • Antiviral agent
  • Aptamer
  • Diagnostics
  • Oligonucleotide phosphorodithioate
  • Oligonucleotide phosphorothioate
  • Therapeutics
  • Thioaptamer

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Yang, X., Wang, H., Beasley, D., Volk, D. E., Zhao, X., Luxon, B. A., ... Gorenstein, D. G. (2006). Selection of thioaptamers for diagnostics and therapeutics. In Annals of the New York Academy of Sciences (Vol. 1082, pp. 116-119). (Annals of the New York Academy of Sciences; Vol. 1082). https://doi.org/10.1196/annals.1348.065

Selection of thioaptamers for diagnostics and therapeutics. / Yang, Xianbin; Wang, He; Beasley, David; Volk, David E.; Zhao, Xu; Luxon, Bruce A.; Lomas, Lee O.; Herzog, Norbert K.; Aronson, Judith; Barrett, Alan; Leary, James F.; Gorenstein, David G.

Annals of the New York Academy of Sciences. Vol. 1082 2006. p. 116-119 (Annals of the New York Academy of Sciences; Vol. 1082).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Yang, X, Wang, H, Beasley, D, Volk, DE, Zhao, X, Luxon, BA, Lomas, LO, Herzog, NK, Aronson, J, Barrett, A, Leary, JF & Gorenstein, DG 2006, Selection of thioaptamers for diagnostics and therapeutics. in Annals of the New York Academy of Sciences. vol. 1082, Annals of the New York Academy of Sciences, vol. 1082, pp. 116-119. https://doi.org/10.1196/annals.1348.065
Yang X, Wang H, Beasley D, Volk DE, Zhao X, Luxon BA et al. Selection of thioaptamers for diagnostics and therapeutics. In Annals of the New York Academy of Sciences. Vol. 1082. 2006. p. 116-119. (Annals of the New York Academy of Sciences). https://doi.org/10.1196/annals.1348.065
Yang, Xianbin ; Wang, He ; Beasley, David ; Volk, David E. ; Zhao, Xu ; Luxon, Bruce A. ; Lomas, Lee O. ; Herzog, Norbert K. ; Aronson, Judith ; Barrett, Alan ; Leary, James F. ; Gorenstein, David G. / Selection of thioaptamers for diagnostics and therapeutics. Annals of the New York Academy of Sciences. Vol. 1082 2006. pp. 116-119 (Annals of the New York Academy of Sciences).
@inproceedings{0b05d62d263545f3842e4df7109ddb58,
title = "Selection of thioaptamers for diagnostics and therapeutics",
abstract = "Thioaptamers offer advantages over normal phosphate ester backbone aptamers due to their enhanced affinity, specificity, and higher stability, largely due to the properties of the sulfur backbone modifications. Over the past several years, in vitro thioaptamer selection and bead-based thioaptamer selection techniques have been developed in our laboratory. Furthermore, several thioaptamers targeting specific proteins such as transcription factor NF-κ and AP-1 proteins have been identified. Selected thioaptamers have been shown diagnostic promise in proteome screens. Moreover, some promising thioaptamers have been shown in preliminary animal therapeutic dosing to increase survival in animal models of infection with West Nile virus.",
keywords = "Antiviral agent, Aptamer, Diagnostics, Oligonucleotide phosphorodithioate, Oligonucleotide phosphorothioate, Therapeutics, Thioaptamer",
author = "Xianbin Yang and He Wang and David Beasley and Volk, {David E.} and Xu Zhao and Luxon, {Bruce A.} and Lomas, {Lee O.} and Herzog, {Norbert K.} and Judith Aronson and Alan Barrett and Leary, {James F.} and Gorenstein, {David G.}",
year = "2006",
month = "10",
doi = "10.1196/annals.1348.065",
language = "English (US)",
isbn = "1573315877",
volume = "1082",
series = "Annals of the New York Academy of Sciences",
pages = "116--119",
booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - Selection of thioaptamers for diagnostics and therapeutics

AU - Yang, Xianbin

AU - Wang, He

AU - Beasley, David

AU - Volk, David E.

AU - Zhao, Xu

AU - Luxon, Bruce A.

AU - Lomas, Lee O.

AU - Herzog, Norbert K.

AU - Aronson, Judith

AU - Barrett, Alan

AU - Leary, James F.

AU - Gorenstein, David G.

PY - 2006/10

Y1 - 2006/10

N2 - Thioaptamers offer advantages over normal phosphate ester backbone aptamers due to their enhanced affinity, specificity, and higher stability, largely due to the properties of the sulfur backbone modifications. Over the past several years, in vitro thioaptamer selection and bead-based thioaptamer selection techniques have been developed in our laboratory. Furthermore, several thioaptamers targeting specific proteins such as transcription factor NF-κ and AP-1 proteins have been identified. Selected thioaptamers have been shown diagnostic promise in proteome screens. Moreover, some promising thioaptamers have been shown in preliminary animal therapeutic dosing to increase survival in animal models of infection with West Nile virus.

AB - Thioaptamers offer advantages over normal phosphate ester backbone aptamers due to their enhanced affinity, specificity, and higher stability, largely due to the properties of the sulfur backbone modifications. Over the past several years, in vitro thioaptamer selection and bead-based thioaptamer selection techniques have been developed in our laboratory. Furthermore, several thioaptamers targeting specific proteins such as transcription factor NF-κ and AP-1 proteins have been identified. Selected thioaptamers have been shown diagnostic promise in proteome screens. Moreover, some promising thioaptamers have been shown in preliminary animal therapeutic dosing to increase survival in animal models of infection with West Nile virus.

KW - Antiviral agent

KW - Aptamer

KW - Diagnostics

KW - Oligonucleotide phosphorodithioate

KW - Oligonucleotide phosphorothioate

KW - Therapeutics

KW - Thioaptamer

UR - http://www.scopus.com/inward/record.url?scp=33845637846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845637846&partnerID=8YFLogxK

U2 - 10.1196/annals.1348.065

DO - 10.1196/annals.1348.065

M3 - Conference contribution

C2 - 17145932

AN - SCOPUS:33845637846

SN - 1573315877

SN - 9781573315876

VL - 1082

T3 - Annals of the New York Academy of Sciences

SP - 116

EP - 119

BT - Annals of the New York Academy of Sciences

ER -